Private equity’s presence in gastroenterology in 2026 is beginning to look different than it has in previous years as deals slow down in volume but grow in size.At the same time, PE groups and GI stakeholders alike continue to respond to new waves of regulatory reforms shaping the scope and impact of PE activity in the space.
Gastroenterology and private equity in 2026: 5 notes (Becker’s GI & Endoscopy)
0